Global PD-1 and PDL-1 Inhibitors Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
According to our (Global Info Research) latest study, the global PD-1 and PDL-1 Inhibitors market size was valued at USD 40690 million in 2022 and is forecast to a readjusted size of USD 64070 million by 2029 with a CAGR of 6.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
This report is a detailed and comprehensive analysis for global PD-1 and PDL-1 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-1 and PDL-1 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1 and PDL-1 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1 and PDL-1 Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc., Agenus Inc and F. Hoffmann-La Roche Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
PD-1 and PDL-1 Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe PD-1 and PDL-1 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1 and PDL-1 Inhibitors, with price, sales, revenue and global market share of PD-1 and PDL-1 Inhibitors from 2018 to 2023.
Chapter 3, the PD-1 and PDL-1 Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1 and PDL-1 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PD-1 and PDL-1 Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1 and PDL-1 Inhibitors.
Chapter 14 and 15, to describe PD-1 and PDL-1 Inhibitors sales channel, distributors, customers, research findings and conclusion.
According to our (Global Info Research) latest study, the global PD-1 and PDL-1 Inhibitors market size was valued at USD 40690 million in 2022 and is forecast to a readjusted size of USD 64070 million by 2029 with a CAGR of 6.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
This report is a detailed and comprehensive analysis for global PD-1 and PDL-1 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-1 and PDL-1 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global PD-1 and PDL-1 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1 and PDL-1 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1 and PDL-1 Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc., Agenus Inc and F. Hoffmann-La Roche Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
PD-1 and PDL-1 Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Pembrolizumab
- Nivolumab
- Atezolizumab
- Durvalumab
- Avelumab
- Stomach Cancer
- Liver Cancer
- Kidney Ccancer
- Bladder Cancer
- Cervical Cancer
- Other
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Arcus Biosciences, Inc.
- Agenus Inc
- F. Hoffmann-La Roche Ltd
- Astra Zeneca PLC
- Beigene Ltd
- Incyte Corporation
- Biocad
- CStone Pharmaceuticals
- Shanghai Junshi Bioscience Co. Ltd
- Shanghai Henlius Biotech, Inc.
- Jiangsu HengRui Medicine Co., Ltd.
- Lee's Pharmaceutical Limited
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe PD-1 and PDL-1 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1 and PDL-1 Inhibitors, with price, sales, revenue and global market share of PD-1 and PDL-1 Inhibitors from 2018 to 2023.
Chapter 3, the PD-1 and PDL-1 Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1 and PDL-1 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PD-1 and PDL-1 Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1 and PDL-1 Inhibitors.
Chapter 14 and 15, to describe PD-1 and PDL-1 Inhibitors sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of PD-1 and PDL-1 Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PD-1 and PDL-1 Inhibitors Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Pembrolizumab
1.3.3 Nivolumab
1.3.4 Atezolizumab
1.3.5 Durvalumab
1.3.6 Avelumab
1.4 Market Analysis by Application
1.4.1 Overview: Global PD-1 and PDL-1 Inhibitors Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Stomach Cancer
1.4.3 Liver Cancer
1.4.4 Kidney Ccancer
1.4.5 Bladder Cancer
1.4.6 Cervical Cancer
1.4.7 Other
1.5 Global PD-1 and PDL-1 Inhibitors Market Size & Forecast
1.5.1 Global PD-1 and PDL-1 Inhibitors Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PD-1 and PDL-1 Inhibitors Sales Quantity (2018-2029)
1.5.3 Global PD-1 and PDL-1 Inhibitors Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 GlaxoSmithKline plc
2.1.1 GlaxoSmithKline plc Details
2.1.2 GlaxoSmithKline plc Major Business
2.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product and Services
2.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 GlaxoSmithKline plc Recent Developments/Updates
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product and Services
2.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.3 Arcus Biosciences, Inc.
2.3.1 Arcus Biosciences, Inc. Details
2.3.2 Arcus Biosciences, Inc. Major Business
2.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product and Services
2.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Arcus Biosciences, Inc. Recent Developments/Updates
2.4 Agenus Inc
2.4.1 Agenus Inc Details
2.4.2 Agenus Inc Major Business
2.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Product and Services
2.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Agenus Inc Recent Developments/Updates
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business
2.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.6 Astra Zeneca PLC
2.6.1 Astra Zeneca PLC Details
2.6.2 Astra Zeneca PLC Major Business
2.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product and Services
2.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Astra Zeneca PLC Recent Developments/Updates
2.7 Beigene Ltd
2.7.1 Beigene Ltd Details
2.7.2 Beigene Ltd Major Business
2.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Beigene Ltd Recent Developments/Updates
2.8 Incyte Corporation
2.8.1 Incyte Corporation Details
2.8.2 Incyte Corporation Major Business
2.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Product and Services
2.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Incyte Corporation Recent Developments/Updates
2.9 Biocad
2.9.1 Biocad Details
2.9.2 Biocad Major Business
2.9.3 Biocad PD-1 and PDL-1 Inhibitors Product and Services
2.9.4 Biocad PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Biocad Recent Developments/Updates
2.10 CStone Pharmaceuticals
2.10.1 CStone Pharmaceuticals Details
2.10.2 CStone Pharmaceuticals Major Business
2.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product and Services
2.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CStone Pharmaceuticals Recent Developments/Updates
2.11 Shanghai Junshi Bioscience Co. Ltd
2.11.1 Shanghai Junshi Bioscience Co. Ltd Details
2.11.2 Shanghai Junshi Bioscience Co. Ltd Major Business
2.11.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.11.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
2.12 Shanghai Henlius Biotech, Inc.
2.12.1 Shanghai Henlius Biotech, Inc. Details
2.12.2 Shanghai Henlius Biotech, Inc. Major Business
2.12.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product and Services
2.12.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
2.13 Jiangsu HengRui Medicine Co., Ltd.
2.13.1 Jiangsu HengRui Medicine Co., Ltd. Details
2.13.2 Jiangsu HengRui Medicine Co., Ltd. Major Business
2.13.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product and Services
2.13.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
2.14 Lee's Pharmaceutical Limited
2.14.1 Lee's Pharmaceutical Limited Details
2.14.2 Lee's Pharmaceutical Limited Major Business
2.14.3 Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Product and Services
2.14.4 Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Lee's Pharmaceutical Limited Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PD-1 AND PDL-1 INHIBITORS BY MANUFACTURER
3.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Manufacturer (2018-2023)
3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturer (2018-2023)
3.3 Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PD-1 and PDL-1 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PD-1 and PDL-1 Inhibitors Manufacturer Market Share in 2022
3.4.2 Top 6 PD-1 and PDL-1 Inhibitors Manufacturer Market Share in 2022
3.5 PD-1 and PDL-1 Inhibitors Market: Overall Company Footprint Analysis
3.5.1 PD-1 and PDL-1 Inhibitors Market: Region Footprint
3.5.2 PD-1 and PDL-1 Inhibitors Market: Company Product Type Footprint
3.5.3 PD-1 and PDL-1 Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global PD-1 and PDL-1 Inhibitors Market Size by Region
4.1.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2029)
4.1.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2029)
4.1.3 Global PD-1 and PDL-1 Inhibitors Average Price by Region (2018-2029)
4.2 North America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.3 Europe PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.4 Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.5 South America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.6 Middle East and Africa PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
5.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2018-2029)
5.3 Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
6.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2018-2029)
6.3 Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
7.2 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
7.3 North America PD-1 and PDL-1 Inhibitors Market Size by Country
7.3.1 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
7.3.2 North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
8.2 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
8.3 Europe PD-1 and PDL-1 Inhibitors Market Size by Country
8.3.1 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
8.3.2 Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PD-1 and PDL-1 Inhibitors Market Size by Region
9.3.1 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
10.2 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
10.3 South America PD-1 and PDL-1 Inhibitors Market Size by Country
10.3.1 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
10.3.2 South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PD-1 and PDL-1 Inhibitors Market Size by Country
11.3.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 PD-1 and PDL-1 Inhibitors Market Drivers
12.2 PD-1 and PDL-1 Inhibitors Market Restraints
12.3 PD-1 and PDL-1 Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of PD-1 and PDL-1 Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of PD-1 and PDL-1 Inhibitors
13.3 PD-1 and PDL-1 Inhibitors Production Process
13.4 PD-1 and PDL-1 Inhibitors Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PD-1 and PDL-1 Inhibitors Typical Distributors
14.3 PD-1 and PDL-1 Inhibitors Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of PD-1 and PDL-1 Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PD-1 and PDL-1 Inhibitors Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Pembrolizumab
1.3.3 Nivolumab
1.3.4 Atezolizumab
1.3.5 Durvalumab
1.3.6 Avelumab
1.4 Market Analysis by Application
1.4.1 Overview: Global PD-1 and PDL-1 Inhibitors Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Stomach Cancer
1.4.3 Liver Cancer
1.4.4 Kidney Ccancer
1.4.5 Bladder Cancer
1.4.6 Cervical Cancer
1.4.7 Other
1.5 Global PD-1 and PDL-1 Inhibitors Market Size & Forecast
1.5.1 Global PD-1 and PDL-1 Inhibitors Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PD-1 and PDL-1 Inhibitors Sales Quantity (2018-2029)
1.5.3 Global PD-1 and PDL-1 Inhibitors Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 GlaxoSmithKline plc
2.1.1 GlaxoSmithKline plc Details
2.1.2 GlaxoSmithKline plc Major Business
2.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product and Services
2.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 GlaxoSmithKline plc Recent Developments/Updates
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product and Services
2.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.3 Arcus Biosciences, Inc.
2.3.1 Arcus Biosciences, Inc. Details
2.3.2 Arcus Biosciences, Inc. Major Business
2.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product and Services
2.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Arcus Biosciences, Inc. Recent Developments/Updates
2.4 Agenus Inc
2.4.1 Agenus Inc Details
2.4.2 Agenus Inc Major Business
2.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Product and Services
2.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Agenus Inc Recent Developments/Updates
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business
2.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.6 Astra Zeneca PLC
2.6.1 Astra Zeneca PLC Details
2.6.2 Astra Zeneca PLC Major Business
2.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product and Services
2.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Astra Zeneca PLC Recent Developments/Updates
2.7 Beigene Ltd
2.7.1 Beigene Ltd Details
2.7.2 Beigene Ltd Major Business
2.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Beigene Ltd Recent Developments/Updates
2.8 Incyte Corporation
2.8.1 Incyte Corporation Details
2.8.2 Incyte Corporation Major Business
2.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Product and Services
2.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Incyte Corporation Recent Developments/Updates
2.9 Biocad
2.9.1 Biocad Details
2.9.2 Biocad Major Business
2.9.3 Biocad PD-1 and PDL-1 Inhibitors Product and Services
2.9.4 Biocad PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Biocad Recent Developments/Updates
2.10 CStone Pharmaceuticals
2.10.1 CStone Pharmaceuticals Details
2.10.2 CStone Pharmaceuticals Major Business
2.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product and Services
2.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CStone Pharmaceuticals Recent Developments/Updates
2.11 Shanghai Junshi Bioscience Co. Ltd
2.11.1 Shanghai Junshi Bioscience Co. Ltd Details
2.11.2 Shanghai Junshi Bioscience Co. Ltd Major Business
2.11.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product and Services
2.11.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
2.12 Shanghai Henlius Biotech, Inc.
2.12.1 Shanghai Henlius Biotech, Inc. Details
2.12.2 Shanghai Henlius Biotech, Inc. Major Business
2.12.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product and Services
2.12.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
2.13 Jiangsu HengRui Medicine Co., Ltd.
2.13.1 Jiangsu HengRui Medicine Co., Ltd. Details
2.13.2 Jiangsu HengRui Medicine Co., Ltd. Major Business
2.13.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product and Services
2.13.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
2.14 Lee's Pharmaceutical Limited
2.14.1 Lee's Pharmaceutical Limited Details
2.14.2 Lee's Pharmaceutical Limited Major Business
2.14.3 Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Product and Services
2.14.4 Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Lee's Pharmaceutical Limited Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PD-1 AND PDL-1 INHIBITORS BY MANUFACTURER
3.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Manufacturer (2018-2023)
3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturer (2018-2023)
3.3 Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PD-1 and PDL-1 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PD-1 and PDL-1 Inhibitors Manufacturer Market Share in 2022
3.4.2 Top 6 PD-1 and PDL-1 Inhibitors Manufacturer Market Share in 2022
3.5 PD-1 and PDL-1 Inhibitors Market: Overall Company Footprint Analysis
3.5.1 PD-1 and PDL-1 Inhibitors Market: Region Footprint
3.5.2 PD-1 and PDL-1 Inhibitors Market: Company Product Type Footprint
3.5.3 PD-1 and PDL-1 Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global PD-1 and PDL-1 Inhibitors Market Size by Region
4.1.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2029)
4.1.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2029)
4.1.3 Global PD-1 and PDL-1 Inhibitors Average Price by Region (2018-2029)
4.2 North America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.3 Europe PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.4 Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.5 South America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
4.6 Middle East and Africa PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
5.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2018-2029)
5.3 Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
6.2 Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2018-2029)
6.3 Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
7.2 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
7.3 North America PD-1 and PDL-1 Inhibitors Market Size by Country
7.3.1 North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
7.3.2 North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
8.2 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
8.3 Europe PD-1 and PDL-1 Inhibitors Market Size by Country
8.3.1 Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
8.3.2 Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PD-1 and PDL-1 Inhibitors Market Size by Region
9.3.1 Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
10.2 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
10.3 South America PD-1 and PDL-1 Inhibitors Market Size by Country
10.3.1 South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
10.3.2 South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PD-1 and PDL-1 Inhibitors Market Size by Country
11.3.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 PD-1 and PDL-1 Inhibitors Market Drivers
12.2 PD-1 and PDL-1 Inhibitors Market Restraints
12.3 PD-1 and PDL-1 Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of PD-1 and PDL-1 Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of PD-1 and PDL-1 Inhibitors
13.3 PD-1 and PDL-1 Inhibitors Production Process
13.4 PD-1 and PDL-1 Inhibitors Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PD-1 and PDL-1 Inhibitors Typical Distributors
14.3 PD-1 and PDL-1 Inhibitors Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 4. GlaxoSmithKline plc Major Business
Table 5. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product and Services
Table 6. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. GlaxoSmithKline plc Recent Developments/Updates
Table 8. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 9. Bristol-Myers Squibb Company Major Business
Table 10. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product and Services
Table 11. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Bristol-Myers Squibb Company Recent Developments/Updates
Table 13. Arcus Biosciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Arcus Biosciences, Inc. Major Business
Table 15. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product and Services
Table 16. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Arcus Biosciences, Inc. Recent Developments/Updates
Table 18. Agenus Inc Basic Information, Manufacturing Base and Competitors
Table 19. Agenus Inc Major Business
Table 20. Agenus Inc PD-1 and PDL-1 Inhibitors Product and Services
Table 21. Agenus Inc PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Agenus Inc Recent Developments/Updates
Table 23. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 24. F. Hoffmann-La Roche Ltd Major Business
Table 25. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 26. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 28. Astra Zeneca PLC Basic Information, Manufacturing Base and Competitors
Table 29. Astra Zeneca PLC Major Business
Table 30. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product and Services
Table 31. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Astra Zeneca PLC Recent Developments/Updates
Table 33. Beigene Ltd Basic Information, Manufacturing Base and Competitors
Table 34. Beigene Ltd Major Business
Table 35. Beigene Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 36. Beigene Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Beigene Ltd Recent Developments/Updates
Table 38. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 39. Incyte Corporation Major Business
Table 40. Incyte Corporation PD-1 and PDL-1 Inhibitors Product and Services
Table 41. Incyte Corporation PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Incyte Corporation Recent Developments/Updates
Table 43. Biocad Basic Information, Manufacturing Base and Competitors
Table 44. Biocad Major Business
Table 45. Biocad PD-1 and PDL-1 Inhibitors Product and Services
Table 46. Biocad PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Biocad Recent Developments/Updates
Table 48. CStone Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 49. CStone Pharmaceuticals Major Business
Table 50. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product and Services
Table 51. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. CStone Pharmaceuticals Recent Developments/Updates
Table 53. Shanghai Junshi Bioscience Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 54. Shanghai Junshi Bioscience Co. Ltd Major Business
Table 55. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 56. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
Table 58. Shanghai Henlius Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 59. Shanghai Henlius Biotech, Inc. Major Business
Table 60. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product and Services
Table 61. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Shanghai Henlius Biotech, Inc. Recent Developments/Updates
Table 63. Jiangsu HengRui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 64. Jiangsu HengRui Medicine Co., Ltd. Major Business
Table 65. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product and Services
Table 66. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 68. Lee's Pharmaceutical Limited Basic Information, Manufacturing Base and Competitors
Table 69. Lee's Pharmaceutical Limited Major Business
Table 70. Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Product and Services
Table 71. Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Lee's Pharmaceutical Limited Recent Developments/Updates
Table 73. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in PD-1 and PDL-1 Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and PD-1 and PDL-1 Inhibitors Production Site of Key Manufacturer
Table 78. PD-1 and PDL-1 Inhibitors Market: Company Product Type Footprint
Table 79. PD-1 and PDL-1 Inhibitors Market: Company Product Application Footprint
Table 80. PD-1 and PDL-1 Inhibitors New Market Entrants and Barriers to Market Entry
Table 81. PD-1 and PDL-1 Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global PD-1 and PDL-1 Inhibitors Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global PD-1 and PDL-1 Inhibitors Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 140. PD-1 and PDL-1 Inhibitors Raw Material
Table 141. Key Manufacturers of PD-1 and PDL-1 Inhibitors Raw Materials
Table 142. PD-1 and PDL-1 Inhibitors Typical Distributors
Table 143. PD-1 and PDL-1 Inhibitors Typical Customers
Table 1. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 4. GlaxoSmithKline plc Major Business
Table 5. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product and Services
Table 6. GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. GlaxoSmithKline plc Recent Developments/Updates
Table 8. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 9. Bristol-Myers Squibb Company Major Business
Table 10. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product and Services
Table 11. Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Bristol-Myers Squibb Company Recent Developments/Updates
Table 13. Arcus Biosciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Arcus Biosciences, Inc. Major Business
Table 15. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product and Services
Table 16. Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Arcus Biosciences, Inc. Recent Developments/Updates
Table 18. Agenus Inc Basic Information, Manufacturing Base and Competitors
Table 19. Agenus Inc Major Business
Table 20. Agenus Inc PD-1 and PDL-1 Inhibitors Product and Services
Table 21. Agenus Inc PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Agenus Inc Recent Developments/Updates
Table 23. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 24. F. Hoffmann-La Roche Ltd Major Business
Table 25. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 26. F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 28. Astra Zeneca PLC Basic Information, Manufacturing Base and Competitors
Table 29. Astra Zeneca PLC Major Business
Table 30. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product and Services
Table 31. Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Astra Zeneca PLC Recent Developments/Updates
Table 33. Beigene Ltd Basic Information, Manufacturing Base and Competitors
Table 34. Beigene Ltd Major Business
Table 35. Beigene Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 36. Beigene Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Beigene Ltd Recent Developments/Updates
Table 38. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 39. Incyte Corporation Major Business
Table 40. Incyte Corporation PD-1 and PDL-1 Inhibitors Product and Services
Table 41. Incyte Corporation PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Incyte Corporation Recent Developments/Updates
Table 43. Biocad Basic Information, Manufacturing Base and Competitors
Table 44. Biocad Major Business
Table 45. Biocad PD-1 and PDL-1 Inhibitors Product and Services
Table 46. Biocad PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Biocad Recent Developments/Updates
Table 48. CStone Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 49. CStone Pharmaceuticals Major Business
Table 50. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product and Services
Table 51. CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. CStone Pharmaceuticals Recent Developments/Updates
Table 53. Shanghai Junshi Bioscience Co. Ltd Basic Information, Manufacturing Base and Competitors
Table 54. Shanghai Junshi Bioscience Co. Ltd Major Business
Table 55. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product and Services
Table 56. Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
Table 58. Shanghai Henlius Biotech, Inc. Basic Information, Manufacturing Base and Competitors
Table 59. Shanghai Henlius Biotech, Inc. Major Business
Table 60. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product and Services
Table 61. Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Shanghai Henlius Biotech, Inc. Recent Developments/Updates
Table 63. Jiangsu HengRui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 64. Jiangsu HengRui Medicine Co., Ltd. Major Business
Table 65. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product and Services
Table 66. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 68. Lee's Pharmaceutical Limited Basic Information, Manufacturing Base and Competitors
Table 69. Lee's Pharmaceutical Limited Major Business
Table 70. Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Product and Services
Table 71. Lee's Pharmaceutical Limited PD-1 and PDL-1 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Lee's Pharmaceutical Limited Recent Developments/Updates
Table 73. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global PD-1 and PDL-1 Inhibitors Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in PD-1 and PDL-1 Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and PD-1 and PDL-1 Inhibitors Production Site of Key Manufacturer
Table 78. PD-1 and PDL-1 Inhibitors Market: Company Product Type Footprint
Table 79. PD-1 and PDL-1 Inhibitors Market: Company Product Application Footprint
Table 80. PD-1 and PDL-1 Inhibitors New Market Entrants and Barriers to Market Entry
Table 81. PD-1 and PDL-1 Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global PD-1 and PDL-1 Inhibitors Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global PD-1 and PDL-1 Inhibitors Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America PD-1 and PDL-1 Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America PD-1 and PDL-1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 140. PD-1 and PDL-1 Inhibitors Raw Material
Table 141. Key Manufacturers of PD-1 and PDL-1 Inhibitors Raw Materials
Table 142. PD-1 and PDL-1 Inhibitors Typical Distributors
Table 143. PD-1 and PDL-1 Inhibitors Typical Customers
LIST OF FIGURES
Figure 1. PD-1 and PDL-1 Inhibitors Picture
Figure 2. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Type in 2022
Figure 4. Pembrolizumab Examples
Figure 5. Nivolumab Examples
Figure 6. Atezolizumab Examples
Figure 7. Durvalumab Examples
Figure 8. Avelumab Examples
Figure 9. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Application in 2022
Figure 11. Stomach Cancer Examples
Figure 12. Liver Cancer Examples
Figure 13. Kidney Ccancer Examples
Figure 14. Bladder Cancer Examples
Figure 15. Cervical Cancer Examples
Figure 16. Other Examples
Figure 17. Global PD-1 and PDL-1 Inhibitors Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 18. Global PD-1 and PDL-1 Inhibitors Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 19. Global PD-1 and PDL-1 Inhibitors Sales Quantity (2018-2029) & (K Units)
Figure 20. Global PD-1 and PDL-1 Inhibitors Average Price (2018-2029) & (US$/Unit)
Figure 21. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Manufacturer in 2022
Figure 22. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Manufacturer in 2022
Figure 23. Producer Shipments of PD-1 and PDL-1 Inhibitors by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 24. Top 3 PD-1 and PDL-1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Top 6 PD-1 and PDL-1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 26. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 27. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 28. North America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 29. Europe PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 30. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 31. South America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 32. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 33. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 34. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Type (2018-2029)
Figure 35. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2029) & (US$/Unit)
Figure 36. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 37. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Application (2018-2029)
Figure 38. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2029) & (US$/Unit)
Figure 39. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 40. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 41. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 42. North America PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 43. United States PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Canada PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Mexico PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 47. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 48. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 49. Europe PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 50. Germany PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. France PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. United Kingdom PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Russia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Italy PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 56. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 57. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 58. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 59. China PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Japan PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Korea PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. India PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Southeast Asia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Australia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 66. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 67. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 68. South America PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 69. Brazil PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Argentina PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 72. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 73. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 74. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 75. Turkey PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Egypt PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Saudi Arabia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. South Africa PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 79. PD-1 and PDL-1 Inhibitors Market Drivers
Figure 80. PD-1 and PDL-1 Inhibitors Market Restraints
Figure 81. PD-1 and PDL-1 Inhibitors Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors in 2022
Figure 84. Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
Figure 85. PD-1 and PDL-1 Inhibitors Industrial Chain
Figure 86. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 87. Direct Channel Pros & Cons
Figure 88. Indirect Channel Pros & Cons
Figure 89. Methodology
Figure 90. Research Process and Data Source
Figure 1. PD-1 and PDL-1 Inhibitors Picture
Figure 2. Global PD-1 and PDL-1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Type in 2022
Figure 4. Pembrolizumab Examples
Figure 5. Nivolumab Examples
Figure 6. Atezolizumab Examples
Figure 7. Durvalumab Examples
Figure 8. Avelumab Examples
Figure 9. Global PD-1 and PDL-1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Application in 2022
Figure 11. Stomach Cancer Examples
Figure 12. Liver Cancer Examples
Figure 13. Kidney Ccancer Examples
Figure 14. Bladder Cancer Examples
Figure 15. Cervical Cancer Examples
Figure 16. Other Examples
Figure 17. Global PD-1 and PDL-1 Inhibitors Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 18. Global PD-1 and PDL-1 Inhibitors Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 19. Global PD-1 and PDL-1 Inhibitors Sales Quantity (2018-2029) & (K Units)
Figure 20. Global PD-1 and PDL-1 Inhibitors Average Price (2018-2029) & (US$/Unit)
Figure 21. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Manufacturer in 2022
Figure 22. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Manufacturer in 2022
Figure 23. Producer Shipments of PD-1 and PDL-1 Inhibitors by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 24. Top 3 PD-1 and PDL-1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Top 6 PD-1 and PDL-1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 26. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 27. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 28. North America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 29. Europe PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 30. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 31. South America PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 32. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 33. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 34. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Type (2018-2029)
Figure 35. Global PD-1 and PDL-1 Inhibitors Average Price by Type (2018-2029) & (US$/Unit)
Figure 36. Global PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 37. Global PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Application (2018-2029)
Figure 38. Global PD-1 and PDL-1 Inhibitors Average Price by Application (2018-2029) & (US$/Unit)
Figure 39. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 40. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 41. North America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 42. North America PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 43. United States PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Canada PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Mexico PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 47. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 48. Europe PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 49. Europe PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 50. Germany PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. France PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. United Kingdom PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Russia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Italy PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 56. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 57. Asia-Pacific PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 58. Asia-Pacific PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 59. China PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Japan PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Korea PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. India PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Southeast Asia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Australia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 66. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 67. South America PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 68. South America PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 69. Brazil PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Argentina PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 72. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 73. Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 74. Middle East & Africa PD-1 and PDL-1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 75. Turkey PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Egypt PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Saudi Arabia PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. South Africa PD-1 and PDL-1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 79. PD-1 and PDL-1 Inhibitors Market Drivers
Figure 80. PD-1 and PDL-1 Inhibitors Market Restraints
Figure 81. PD-1 and PDL-1 Inhibitors Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors in 2022
Figure 84. Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors
Figure 85. PD-1 and PDL-1 Inhibitors Industrial Chain
Figure 86. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 87. Direct Channel Pros & Cons
Figure 88. Indirect Channel Pros & Cons
Figure 89. Methodology
Figure 90. Research Process and Data Source
